Home・Akciju saraksts・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

109.34 -2.43

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

108.84

Max

112.91

Galvenie mērījumi
By Trading Economics
Ienākumi	-130M -32M
Pārdošana	-37M 165M
P/E Sektora vidējais	260.343 64.641
EPS	-0.3
Peļņas marža	-19.26
Darbinieki	730
EBITDA	-55M -44M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+8.69% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 3. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.8B 9.8B
Iepriekšējā atvēršanas cena	111.77
Iepriekšējā slēgšanas cena	109.34

Corcept Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

2026. g. 3. aug. 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

2026. g. 31. jūl. 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

2026. g. 30. jūl. 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

2026. g. 29. jūl. 23:41 UTC

Social Media

News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

2026. g. 28. jūl. 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

2026. g. 27. jūl. 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

2026. g. 24. jūl. 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

2026. g. 22. jūl. 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

2026. g. 20. jūl. 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Salīdzinājums

Cenas izmaiņa

Corcept Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

8.69% augšup

Prognoze 12 mēnešiem

Vidējais 122.6 USD 8.69%

Augstākais 165 USD

Zemākais 50 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Corcept Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Corcept Therapeutics Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.